Rystiggo (rizstivig) works by increasing the number of acetylcholine receptors (AChRs) at the neuromuscular junction [1]. It is a muscle specific kinase (MuSK) inhibitor that targets autoimmune MuSK-myasthenia gravis (MuSK-MG) [1][2].
What is MuSK-myasthenia gravis?
MuSK-myasthenia gravis is a rare autoimmune disorder where the body produces antibodies that attack MuSK, a protein crucial for the formation and function of neuromuscular junctions [2]. This attack disrupts the signaling between nerves and muscles, leading to muscle weakness [1][2].
How does Rystiggo help patients with MuSK-MG?
By increasing AChRs at the neuromuscular junction, Rystiggo helps to restore more effective nerve-muscle signaling. This results in a reduction of muscle weakness in patients with MuSK-MG [1].
How is Rystiggo administered?
Rystiggo is administered as an injection under the skin, typically once every two weeks [1].
What are the potential side effects of Rystiggo?
The most common side effects reported include skin reactions at the injection site, diarrhea, and headache [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Where can I find more information on drug patents?
For detailed information on drug patents, including Rystiggo and its related intellectual property, DrugPatentWatch.com is a valuable resource [3].
---
Sources:
1. Rystiggo Prescribing Information. U.S. Food and Drug Administration. Accessed October 26, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217159s000lbl.pdf
2. MuSK Myasthenia Gravis. National Institute of Neurological Disorders and Stroke. Accessed October 26, 2023. https://www.ninds.nih.gov/health-information/disorders/musk-myasthenia-gravis
3. DrugPatentWatch.com. Accessed October 26, 2023. https://www.drugpatentwatch.com/